Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there. You just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Prognyx turns trials, readouts, deals and regulatory moves into one sourced answer for your asset and your next decision, delivered as a five-business-day pilot. Each claim links to a primary source; automated checks remove what its source does not carry.
[ 01 ] THE PROBLEM
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there. You just can't surface it in time.
A six-figure database hands you data to mine. A consulting project hands you a deck, once. Neither watches your back on a Tuesday afternoon.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
[ 02 ] WHAT PROGNYX DOES
Not a portal to mine or a six-week consulting project. One asset, one indication and one decision question, researched, sourced and delivered as a concise brief.
KRAS G12C, second-line NSCLC
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
[ 03 ] HOW IT WORKS
We map your competitive set, targets, mechanisms, indications and the assets that can move your value.
SCOPEWe track trials, congress readouts, regulatory actions, deals and publications, straight to the primary source.
MONITORWe turn it into what it means for you and what to do next, sharp, sourced, no filler.
ANALYZEYou get briefs your team actually reads and forwards, plus answers on demand when the field shifts.
ACT[ 04 ] WHY PROGNYX
We don't out-database the giants. We out-matter them on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER



Merck's HIF-2alpha inhibitor combination clears Europe's scientific committee for ccRCC after PD-(L)1 therapy, on LITESPARK-011 progression-free survival data.
Read briefing →
Clarity Pharmaceuticals says the FDA granted its copper-64 agent Cu-64 SAR-bisPSMA a breakthrough designation in biochemical recurrence, the first in PSMA PET imaging by…
Read briefing →
The company's ASH 2026 release reports Phase 3 data for the TECVAYLI-TALVEY bispecific pair reducing progression risk in relapsed myeloma as early as second line, plus…
Read briefing →
The IL-15 receptor agonist plus BCG beat BCG alone on the primary endpoint in the 370-patient randomized QUILT-2.005 trial, and ImmunityBio targets a Q4 2026…
Read briefing →[ 06 ] THE OFFER
Tell us the asset, indication and decision you need to clarify. We will confirm the scope and fee of a one-off pilot in writing, delivered in five business days.
How Prognyx knows this
Every claim is built from primary sources only, and traces back to a document you can open. No opinion you can't check.
Who's behind it
Rali Filali, founder of Prognyx · M.D. candidate. Independent, no platform or bank behind the read. Every brief is audited against the primary record before it reaches you. Competitive analysis of public information, not medical or investment advice.
One-off pilot, one asset, one indication and one defined decision question, delivered in five business days with one written revision, at a fixed fee confirmed in writing. See the exact scope
Need it every month? Join the waitlist for a monthly source-linked feed on one target (page, CSV and alerts). See the KRAS G12C example
ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX